<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04660513</url>
  </required_header>
  <id_info>
    <org_study_id>SGH-ENDO-GlycineTA-001</org_study_id>
    <nct_id>NCT04660513</nct_id>
  </id_info>
  <brief_title>Obesity-Related Glycine Deficiency: Investigating a Long-standing Metabolic Paradox Using Bedside and Bench Approaches</brief_title>
  <official_title>Obesity-Related Glycine Deficiency: Investigating a Long-standing Metabolic Paradox Using Bedside and Bench Approaches</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke-NUS Graduate Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National University Health System, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Singapore General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity, in addition to causing abnormal glucose and lipid metabolism, is also associated&#xD;
      with altered plasma concentrations of multiple amino acids, including increased levels of&#xD;
      branched-chain amino acids and decreased levels of glycine. The mechanisms and consequences&#xD;
      of obesity- related glycine deficiency are unknown.&#xD;
&#xD;
      The overall aim of this project is to comprehensively study glycine metabolic pathways in&#xD;
      morbid obesity using stable-isotope tracer techniques in human subjects and validating&#xD;
      kinetic findings using a cell model of oxidative stress.&#xD;
&#xD;
      This will be a single-centre, observational study. 21 individuals with morbid obesity&#xD;
      scheduled for bariatric surgery and 21 non-obese controls will be recruit. They will undergo&#xD;
      different study visits and procedures and the human biological materials collected will be&#xD;
      analysed for as per aims of the studies. We believe that the glycine metabolic pathways,&#xD;
      possibly through the optimization of gluthathione (GSH) synthesis, may provide targets to&#xD;
      develop novel therapeutic agents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metabolic tracers: 1,2-[13C2]-Glycine, 1,2-[13C2]-Glycine, 2,3,3,-[2H3]-Serine and&#xD;
      [2H5]-Phenylalanine will be infused for quantification of various pathways associated with&#xD;
      glycine metabolism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 8, 2018</start_date>
  <completion_date type="Actual">November 4, 2020</completion_date>
  <primary_completion_date type="Actual">November 4, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Glycine kinetic</measure>
    <time_frame>Baseline for all subjects and 5-12 months after bariatric surgery for morbid obesity group</time_frame>
    <description>Differences in glycine kinetic measurements between obese subjects and controls, and within obese subjects after bariatric surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>Baseline for all subjects and 5-12 months after bariatric surgery for morbid obesity group</time_frame>
    <description>Differences in insulin sensitivity between obese subjects and controls, and within obese subjects after bariatric surgery</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">42</enrollment>
  <condition>Glycine Metabolism Disturbances</condition>
  <condition>Insulin Resistance</condition>
  <condition>Morbid Obesity</condition>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>Morbid obesity</arm_group_label>
    <description>BMI 32.5 kg/m2 and above</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-obese healthy controls</arm_group_label>
    <description>BMI below 25 kg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bariatric surgery</intervention_name>
    <description>Subjects with morbid obesity underwent bariatric surgery</description>
    <arm_group_label>Morbid obesity</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Non-obese controls from our healthy volunteer database will be invited to participate.&#xD;
        Obese subjects attending the weight management clinics in the hospital will be referred to&#xD;
        the study team by their attending physicians&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 21-65 years&#xD;
&#xD;
          2. BMI &lt; 25 kg/m2 for non-obese controls or BMI â‰¥ 32.5 kg/m2 for obese subjects scheduled&#xD;
             for bariatric surgery&#xD;
&#xD;
          3. Able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All subjects:&#xD;
&#xD;
          1. Weight &gt; 150 kg&#xD;
&#xD;
          2. Renal impairment (estimated creatinine clearance estimated by Cockcroft-Gault Equation&#xD;
             &lt; 60 ml/min)&#xD;
&#xD;
          3. Haemoglobin concentration &lt; 10 g/L&#xD;
&#xD;
          4. Serum alanine aminotransferase or aspartate aminotransferase above 2x upper limit of&#xD;
             normal&#xD;
&#xD;
          5. Uncontrolled hypertension (BP &gt; 180/110 mmHg)&#xD;
&#xD;
          6. Pregnancy&#xD;
&#xD;
          7. Nursing mothers&#xD;
&#xD;
          8. Significant cardiovascular disease (e.g. acute myocardial infarction, congestive&#xD;
             cardiac failure, ischemic heart disease, atrial fibrillation, sick sinus syndrome,&#xD;
             supraventricular tachycardia)&#xD;
&#xD;
          9. Previous stroke&#xD;
&#xD;
         10. Uncontrolled thyroid disease&#xD;
&#xD;
         11. Surgery requiring general anaesthesia within 4-weeks before enrolment&#xD;
&#xD;
         12. Psychiatric disorders requiring medication&#xD;
&#xD;
         13. Significant alcohol intake (&gt; 1 unit per day for women and &gt; 2 units per day for men)&#xD;
&#xD;
         14. Subcutaneous insulin injections&#xD;
&#xD;
         15. Systemic steroid usage (eg. prednisolone, hydrocortisone, cortisone, dexamethasone)&#xD;
&#xD;
         16. Cancer within the last 5-years (except squamous cell and basal cell cancer of the&#xD;
             skin)&#xD;
&#xD;
         17. Any factors likely to limit adherence to study protocol (e.g. dementia; alcohol or&#xD;
             substance abuse; history of unreliability in medication taking or appointment keeping;&#xD;
             significant concerns about participation in the study from spouse, significant other&#xD;
             or family members)&#xD;
&#xD;
        Non-obese controls 1. Known Diabetes Mellitus (diagnosed according to 2014 Ministry of&#xD;
        Health Clinical Practice Guidelines for Diabetes Mellitus)&#xD;
&#xD;
        Obese subjects&#xD;
&#xD;
        1. HbA1C &lt; 9%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169856</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glycine</keyword>
  <keyword>obesity</keyword>
  <keyword>bariatric surgery</keyword>
  <keyword>gluthathione</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

